Anemia in Elderly Market was valued at USD 6.8 billion and is projected to reach USD 11.4 billion by 2034

Anemia in Elderly Market Overview

The Anemia in Elderly Market is experiencing sustained growth due to the rapidly expanding geriatric population and rising chronic disease burden worldwide. In 2024, the global market was valued at USD 6.8 billion and is projected to reach USD 11.4 billion by 2034, growing at a CAGR of 5.2% during the forecast period. Aging demographics, improved diagnostic capabilities, and advancements in anemia therapeutics are key forces driving market expansion.

Anemia affects a significant portion of individuals aged 65 and above, often linked to chronic kidney disease (CKD), cancer-related anemia, nutritional deficiencies, and anemia of inflammation. As healthcare systems prioritize early detection and chronic disease management, demand for diagnostic tools, oral iron, intravenous iron therapies, and erythropoiesis-stimulating agents continues to rise.

Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71297

Market Dynamics
Drivers
• Rising global elderly population-projected to reach 1.5 billion by 2050-boosting the anemia patient pool.
• Growing prevalence of CKD, cancer, and inflammatory disorders, major contributors to geriatric anemia incidence.
• Technological advancements in diagnostics such as ferritin tests, iron panels, and CRP-based inflammation evaluations.
• High demand for intravenous iron and erythropoiesis-stimulating agents (ESAs) for moderate-severe anemia.
• Government initiatives promoting early detection and nutritional assessment for senior citizens.

Restraints
• High treatment costs, especially for injectable ESAs and IV iron products.
• Underdiagnosis due to symptom overlap with typical aging processes.
• Limited specialist geriatric care in emerging economies.
• High comorbidity load complicating treatment protocols.

Opportunities
• Development of next-generation oral iron formulations with higher absorption and lower GI side effects.
• Biologics and hepcidin modulators emerging as future solutions for anemia of inflammation.
• Growth of telemedicine for elderly patients, enabling continuous follow-up in chronic conditions.
• Expansion of IV iron infusion centers in Asia and Latin America.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71297/anemia-in-elderly-market

Market Segmentation
By Type of Anemia
• Iron Deficiency Anemia
• Vitamin B12 Deficiency Anemia
• Folate Deficiency Anemia
• Anemia of Chronic Disease
• Anemia Associated with Chronic Kidney Disease
• Others (Myelodysplastic syndromes, bone marrow disorders)

By Treatment
• Oral Iron Supplements
• Intravenous Iron (IV iron)
• Vitamin B12 & Folate Supplements
• Erythropoiesis-Stimulating Agents (ESAs)
• Blood Transfusions
• Other Targeted Therapies

By Diagnosis Method
• Complete Blood Count (CBC)
• Ferritin & Iron Study Panels
• Reticulocyte Count
• Kidney Function Tests
• Bone Marrow Examination

By End User
• Hospitals
• Specialty Clinics
• Diagnostic Laboratories
• Home-Care & Long-term Care Facilities

Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71297

Regional Insights
North America
North America held the largest market share in 2024, valued at USD 2.4 billion, supported by strong clinical infrastructure, high rates of CKD-related anemia, and rapid adoption of IV iron and ESA therapies. The region is expected to grow at a CAGR of 4.8%.

Europe
Europe represents a mature market valued at USD 1.9 billion in 2024, driven by universal healthcare systems and robust screening programs. Demand for IV iron therapies continues to rise, particularly in Germany, Italy, and the UK.

Asia-Pacific
The fastest-growing region, Asia-Pacific is projected to expand at a CAGR of 6.5% due to significant increases in elderly populations in China, Japan, and India. The regional market is expected to reach USD 3.2 billion by 2034.

Latin America & Middle East/Africa
These regions are in early growth stages but show strong potential as investments in diagnostic capacity and geriatric health improve. The combined regional market is projected to reach USD 1.1 billion by 2034.

Competitive Landscape
Key companies contributing to diagnostics and treatment include:
• Amgen Inc.
• Pfizer Inc.
• Vifor Pharma
• Roche
• Sanofi S.A.
• Bayer AG
• Daiichi Sankyo Company
• Akebia Therapeutics
• Teva Pharmaceutical Industries
• Bristol Myers Squibb

The market is highly influenced by innovation in ESAs, IV iron formulations, and long-acting biologics targeting anemia associated with chronic disease and kidney dysfunction.

Recent Developments
• Launch of long-acting ESA formulations improving dosing intervals for elderly patients.
• Development of new IV iron products with improved safety profiles and faster infusion times.
• Growing use of AI-enabled diagnostic platforms for anemia detection in primary care settings.
• Increased clinical evidence supporting early intervention to reduce hospitalizations and fall-related complications in seniors.

Future Outlook
The Anemia in Elderly Market is projected to add nearly USD 4.6 billion in new revenue over the next decade. Rising global dependency ratios, growing chronic disease burden, and the modernization of primary healthcare are expected to further boost demand. The next phase of growth will be driven by:

• Biologic therapies targeting inflammatory anemia pathways
• Hepcidin-targeting drugs for anemia of chronic disease
• Advanced geriatric screening programs
• Integrated digital-clinical care models for elderly populations

By 2034, the market is expected to reach USD 11.4 billion, driven by both therapeutic advancements and improved diagnosis rates worldwide.

This report is also available in the following languages : Japanese (高齢者市場の貧血), Korean (노인 시장의 빈혈), Chinese (老年市场贫血症), French (Anémie chez les personnes âgées), German (Anämie bei älteren Menschen), and Italian (Anemia nel mercato degli anziani), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71297

Our More Reports:

Chronic Plaque Psoriasis Market
https://exactitudeconsultancy.com/reports/71377/chronic-plaque-psoriasis-market

Generalized Myasthenia Gravis Market
https://exactitudeconsultancy.com/reports/72089/generalized-myasthenia-gravis-gmg-market

Graves Orbitopathy Market
https://exactitudeconsultancy.com/reports/71315/graves-orbitopathy-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.